Publications

Clinical Guidelines & Position Statements Publication Date
NEW: CRA Position Statement on Citrate-Free Humira (PDF) May 2020
CRA Position Statement on COVID-19 and Hydroxychloroquine Supply (PDF)
Frequently Asked Questions
April 2020
Canadian Rheumatology Association Policy on Potential Conflicts of Interest in the Guideline Development Process (PDF) June 2019
Canadian Rheumatology Association Guidelines Handbook (PDF) May 2019
Canadian Rheumatology Association Position Statement on Biosimilars
Frequently Asked Questions
May 2019
Canadian Rheumatology Association Position Statement on Medical Cannabis Use in Rheumatic Disease
Frequently Asked Questions
January 2019
Canadian Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus August 2018
Canadian Position Statement on Opioid Therapy (PDF) November 2017
Canadian Position Statement on Management of Juvenile Idiopathic Arthritis October 2016
Canadian Position Statement on Ethical Prescribing (PDF) November 2015
Editorial: Expanding Medical Marijuana Access in Canada (PDF) November 2015
Canadian Review on Cannabinoid Treatments for Rheumatic Diseases  November 2015
Canadian Recommendations for the Management of Spondyloarthropathy April 2014
Cardiovascular Risk with Diclofenac:  Response to Health Canada (PDF) November 2014
Chronic pain, Diclofenac and Cardiovascular Risk:  Management Algorithm (PDF) June 2014
Canadian Confidence with Cannabinoids in Rheumatic Diseases:  A Survey of Rheumatologists (PDF) November 2014
Canadian Recommendations for Management of RA August 2012
Canadian Fibromyalgia Guidelines August 2012